2011 Fiscal Year Final Research Report
Development of Redox Controlling Nanomedicine Based on Albumin Fusion
| Project/Area Number |
21390177
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Toru 熊本大学, 薬学部, 教授 (90423657)
WATANABE Hiroshi 熊本大学, 薬学部, 准教授 (70398220)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | ドラッグデリバリー / ヒト血清アルブミン / Thioredoxin 1 / Pichia酵母 / 肺障害 / 抗酸化能 / 酸化ストレス |
|---|
| Research Abstract |
Using albumin fusion technology, a novel redox controlling nanomedicine was designed and evaluated for applications in clinical settings. The results from various studies suggested that HSA-thioredoxin fusion protein has great potential as a therapeutic agent for treating oxidative stress and inflammation related diseases. In addition, a significant tumor metastasis activity from the EPR effect of SNO-HSA dimer has been confirmed. Based on the results of the current studies, preparations for a clinical trial led by a clinician are now in progress.
|
